Can a Gene-Targeting injection make hypertrophic scars fade?

NCT ID NCT05196373

Terminated Symptom relief Sponsor: Sirnaomics Source: ClinicalTrials.gov ↗

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This trial investigates whether STP705, an injection that uses small interfering RNA to block scar-promoting proteins, can safely improve hypertrophic scars. Adults aged 18 to 45 with linear hypertrophic scars will receive weekly injections into the scar for four weeks. The study aims to assess safety and whether the treatment can reduce scar thickness, redness, and stiffness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental injection called STP705, which uses small interfering RNA (siRNA) to block two proteins involved in scar formation
What this could lead to: If it works, this could offer a new way to treat hypertrophic scars by directly targeting the biological processes that cause them.
What could go wrong: This is an early-phase trial with a small number of participants, so the results may not apply to everyone. The injection is experimental, and its safety and effectiveness are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTROPHIC SCAR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cicatrix, Hypertrophic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERTROPHIC SCAR

Contacts and locations

Locations

The 9th Hospital of Shanghai

Shanghai, Shanghai Municipality, 200000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.